First Specific Reversal Agent For A NOAC Distributed In Hospitals As Xarelto Lawsuit Plaintiffs Increase In Number

March 31, 2016 – – BloodThinnerHelp.com reports on a recent article by PR Newswire on the distribution of Praxbind, a reversal agent for Pradaxa that has been widely distributed in hospitals. As a reversal agent for the blood thinning drug, Xarelto, still has not been approved,an antidote for Xarelto’s competitor drug, Pradaxa, has been distributed in 2,200 hospitals nationwide, according to Newswire.

The FDA approved Praxbind in October 2015 for patients specifically treated with Pradaxa, when a reversal effect is needed for emergency surgeries or if a patient is experiencing uncontrollable bleeding, according to the article. Meanwhile, the fact that a reversal agent for Xarelto is still being developed for the drug has been part of several thousand lawsuits that plaintiffs have filed against Xarelto manufacturers, Johnson & Johnson and Bayer AG.

Xarelto was first introduced to the U.S. market in 2011 when the FDA approved the drug for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, atrial fibrillation, and for general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome. Since its approval, lawsuits have been filed alleging that the drug causes adverse side effects about which the companies do not adequately warn the consumer. In addition, many plaintiffs allege that the companies were negligent in their distribution of the drug by downplaying the lack of antidote for the anticoagulant when it was released to the market.

Those cases filed federally have accumulated to almost 3,000 and have been consolidated for more efficient handling through the creation of a multidistrict litigation panel in Eastern Louisiana. Bellwether trials on those cases are expected to take place beginning in February 2017.

As those trial dates approach, Attorney Joseph Osborne is working to make sure that those patients who have used Xarelto and believe they may have suffered serious side effects related to the drug are able to explore their legal rights. Qualifying individuals may be entitled to legal action and financial compensation. Osborne is currently offering free legal consultations for affected parties.

For more information on Xarelto, or to ask questions, contact Joseph Osborne, Esq. at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008998